Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Surface Oncology Inc
(NQ:
SURF
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 7, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Surface Oncology Inc
Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote “FOR” the Proposed Merger with Coherus BioSciences
August 31, 2023
Urges Stockholders to Vote Promptly to Ensure Their Shares are Represented at the September 7th Special Meeting
From
Surface Oncology, Inc.
Via
GlobeNewswire
SURFACE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
August 07, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023
August 02, 2023
From
Surface Oncology, Inc.
Via
GlobeNewswire
SURFACE ONCOLOGY INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Surface Oncology, Inc. - SURF
June 21, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
SURF Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Surface Oncology, Inc. Is Fair to Shareholders
June 16, 2023
From
Halper Sadeh LLC
Via
Business Wire
Coherus to Acquire Surface Oncology
June 16, 2023
From
Surface Oncology, Inc.
Via
GlobeNewswire
Surface Oncology Reports Financial Results and Corporate Highlights for First Quarter 2023
May 04, 2023
From
Surface Oncology, Inc.
Via
GlobeNewswire
Surface Oncology Presents New Preclinical Data on SRF114, a fully human anti-CCR8 antibody, at the AACR Annual Meeting 2023
April 18, 2023
– New in vivo data show SRF114 promotes a pro-inflammatory tumor microenvironment resulting in robust antitumor activity in mouse models –
From
Surface Oncology, Inc.
Via
GlobeNewswire
Surface Oncology to Present New Preclinical SRF114 Data at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 16, 2023
From
Surface Oncology, Inc.
Via
GlobeNewswire
Surface Oncology Reports Financial Results and Corporate Highlights for Fourth Quarter and Full Year 2022
March 09, 2023
From
Surface Oncology, Inc.
Via
GlobeNewswire
Surface Oncology to Participate in the Cowen 43rd Annual Health Care Conference
February 28, 2023
From
Surface Oncology, Inc.
Via
GlobeNewswire
Surface Oncology to Participate in the 2023 Guggenheim Oncology Days Conference
February 02, 2023
From
Surface Oncology, Inc.
Via
GlobeNewswire
Vaccinex Announces First Patient Dosed with Anti-CCR8 Antibody Licensed to Surface Oncology
January 09, 2023
Surface Oncology initiates clinical trial with antibody discovered using Vaccinex’s ActivMAb® Antibody Discovery Platform
From
Vaccinex, Inc.
Via
GlobeNewswire
Surface Oncology Announces First Patient Dosed in a Phase 1/2 Study Evaluating SRF114, a Potential Best-In-Class Anti-CCR8 Antibody, in Patients with Advanced Solid Tumors
January 05, 2023
From
Surface Oncology, Inc.
Via
GlobeNewswire
Surface Oncology to Present Non-clinical Data for SRF388 and SRF114 at the Society for Immunotherapy of Cancer 2022 Annual Meeting
November 07, 2022
Data further support SRF388 and SRF114 clinical development programs
From
Surface Oncology, Inc.
Via
GlobeNewswire
Surface Oncology Announces Promising SRF388 Monotherapy Data in Non-Small Cell Lung Cancer (NSCLC), Opening Second Stage of Monotherapy Trial and NSCLC Pembrolizumab Combination Cohort
November 02, 2022
From
Surface Oncology, Inc.
Via
GlobeNewswire
VIB and Surface Oncology Announce Publication in Cell Reports Revealing IL-27 Structure and the Mechanism of Action for SRF388
October 19, 2022
From
Surface Oncology, Inc.
Via
GlobeNewswire
Global Radiotherapy Market Expected To Reach $7.3 Billion with a CAGR Of 4.2% By 2026
September 20, 2021
Via
FinancialNewsMedia
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.